

Home ► All Journals ► Politics & International Relations ► Review of International Political Economy ► List of Issues ► Volume 17, Issue 4 ► Governing lipitor and lipstick: Capacity

Q

Review of International Political Economy > Volume 17, 2010 - <u>Issue 4</u>: Market Regulation

1,748381ViewsCrossRef citations to dateAltmetricINTRODUCTION

Governing lipitor and lipstick: Capacity, sequencing, and power in international pharmaceutical and cosmetics regulation David Bach & Abraham L. Newman

Pages 665-695 | Published online: 04 Oct 2010

Solution Cite this article **Article** https://doi.org/10.1080/09692291003723706



ABSTRACT

Over the last three decades, the pharmaceutical and cosmetics industries have become increasingly global. To ensure product safety and consumer protection, regulators in leading markets have applied domestic rules extraterritorially and have joined forces to harmonize rules through transgovernmental cooperation. Yet whereas the United States has long been the dominant player in international market regulation of pharmaceuticals, the European Union has decisively shaped global rules for cosmetics. What explains differences in agenda setting power across the two closely-related industries? We compare and contrast the expectations of a realist account focused on market size and a liberal functionalist argument centered on the role of market friction with a historical institutionalist explanation stressing the relative sequential development over time of domestic regulatory capacity in leading markets. The empirical evidence shows that domestic regulatory institutions systematically shape international market regulation. Historical institutionalism provides an important complement to existing transgovernmental research, offering clear expectations for the origins of and terms of influence within such cooperation. More generally, it opens up a rich toolbox for the analysis of industry-level global market governance, which affects the daily lives of many millions of consumers.

KEYWORDS:

Sequencing	transgovernmental politics	regulatory capacity	historical institutionalism	pharmaceuticals
cosmetics				

ACKNOWLEDGEMENTS

This paper has benefitted tremendously from workshops at Temple University, Georgetown University, and UC Berkeley, that led to this special issue; we would like to thank all participants as well as the sponsoring institutions. In particular, we would like to acknowledge the extremely helpful comments and suggestions on various earlier drafts from Adriana Brown, Tim Büthe, Richard Deeg, Dan Drezner, Henry Farrell, Orfeo Fioretos, Kate McNamara, Craig Pollack, Elliot Posner, David Vogel, Steve Vogel, Steve Weber, and John Zysman. Earlier versions were also presented at the Annual Meeting of the International Studies Association, San Francisco, March 26–28, 2008 and the Joint Session of the European Consortium for Political Research (ECPR), Lisbon, April 14–19, 2009. Part of this research was supported by a Spanish Ministry of Science and Innovation grant (ECO2008-01527).

Notes

1 Many issues shape international markets for pharmaceuticals and cosmetics. This paper focuses on the fundamental decision of whether to allow a product to enter the consumer market and the safety standards that producers must follow during production.

2 This argument draws on historical institutional work such as <u>Zysman (1994)</u> and <u>Thelen (2004)</u>.

3 Jurisdictions can consciously build-up regulatory capacity, as happened during the period of telecommunications liberalization, but such build-up does not happen overnight. See (<u>Vogel, 1996</u>; <u>Gilardi, 2002</u>).

4 The paper focuses on structural power embodied in regulatory capacity and not the underlying preferences of the lead regulators. For an examination of preferences see (<u>Singer, 2007</u>).

5 A growing rationalist literature on the design of international institutions considers these questions. See (Koremenos, Lipson and Snidal, 2001).

6 This transposes sequencing arguments developed in the comparative setting to international issues. See (Posner, this issue; Newman 2008b; <u>Pierson, 2004</u>).

7 IMS Health, 2004. IMS World Review. Norwalk, CT.

8 The World Health Situation. Geneva: World Health Organization. Chapter 3.

9 See <u>www.ich.org</u>.

10 See "EMEA inspections growing, get tougher than FDA audits, Wyeth exec says," Warning Letter Bulletin, 12 July 2004.

11 See (<u>Henney, 2001</u>).

12 International Accord on Drug Testing Standards Will Delete LD50 Animal Testing Requirements, F-D-C REP. ("The Blue Sheet"), Nov. 20, 1991, at 9.

13 Data are taken from presentations made in April 2004 and April 2007 by Euromonitor.

14 Data are taken from presentations made in April 2004 and April 2007 by Euromonitor.

15 Author interview with an industry spokesperson. Brussels, 2007.

16 See Shefali Srinivas, "Tougher Regulations for Cosmetics Next Year." Straits Times, November 22, 2007.

17 See the ASEAN Cosmetics Association at http://www.aseancosmetics.org/default.

18 See Laurel Naversen Geraghty, "Should You Worry About the Chemicals in Your Makeup?" The New York Time, July 7, 2005.

19 On the issue of preference formation, see (Fioretos, this issue).

Related Research Data The European regulatory state and global public policy: micro-institutions, macroinfluence Source: Journal of European Public Policy Taking Temporality Seriously: Modeling History and the Use of Narratives as Evidence Source: American Political Science Review How Institutions Evolve Source: Unknown Repository Organizing Babylon - On the Different Conceptions of Policy Networks Source: Public Administration How Institutions Create Historically Rooted Trajectories of Growth Source: Industrial and Corporate Change **Politics in Time** Source: Unknown Repository Policy credibility and delegation to independent regulatory agencies: a comparative empirical analysis Source: Journal of European Public Policy Our epidemiological footprint: The circulation of avian flu, SARS, and HIV/AIDS in the world economy Source: Review of International Political Economy The Globalization of Pharmaceutical Regulation Source: Governance Toward a Positive Theory of International Institutions: Regulating International Aviation Markets Source: International Organization Transatlantic Competition Policy: Domestic and International Sources of EU-US Cooperation Source: European Journal of International Relations Setting International Standards: Technological Rationality or Primacy of Power? Source: World Politics

Dominance, Dependence, and Political Power: Tethering Technology in the 1980s and Today Source: International Studies Quarterly Globalization, harmonization, and competition: the different pathways to policy convergence Source: Journal of European Public Policy Emergent Patterns in the Regulation of Pharmaceuticals: Institutions and Interests in the United States, Canada, Britain, and France Source: Journal of Health Politics Policy and Law Building Transnational Civil Liberties: Transgovernmental Entrepreneurs and the **European Data Privacy Directive** Source: International Organization All Politics Is Global Source: Unknown Repository The second face of hegemony: Britain's repeal of the Corn Laws and the American Walker Tariff of 1846 Source: International Organization **Regulating Europe** Source: Unknown Repository Regional Sales of Multinationals in the World Cosmetics Industry Source: European Management Journal Toward World Antitrust and Market Access Source: The American Journal of International Law Theories and Empirical Studies of International Institutions Source: International Organization Diplomacy and domestic politics: the logic of two-level games Source: International Organization **Global Business Regulation** Source: Unknown Repository "Let's Argue!": Communicative Action in World Politics Source: International Organization Trading risks for markets: the international harmonisation of pharmaceuticals regulation Source: Health Risk & Society All Politics Is Global Source: Unknown Repository Governance in a Global Economy: Political Authority in Transition Source: Political Science and Politics Pharmaceuticals, the state and the global harmonisation process Source: Australian Health Review

The Forging of Bureaucratic Autonomy Source: Unknown Repository **Ruling the Waves** Source: Science International Drug Regulation Source: Annual Review of Public Health Globalization in the 21st Century Source: Unknown Repository The Architecture of International Cooperation: Transgovernmental Networks and the Future of International Law Source: SSRN Electronic Journal Making Rules for Global Finance: Transatlantic Regulatory Cooperation at the Turn of the Millennium Source: International Organization Why States Act through Formal International Organizations Source: Journal of Conflict Resolution The International Politics of Harmonization: The Case of Capital Market Regulation Source: International Organization **Protectors of Privacy** Source: Unknown Repository The Rational Design of International Institutions Source: Unknown Repository Trading up: Consumer and Environmental Regulation in a Global Economy Source: Foreign Affairs Linking provided by Schole Splorer

Related research 1

People also read Recommended articles	Cited by 38
---------------------------------------	----------------

Information for	Open access	
Authors	Overview	
R&D professionals	Open journals	
Editors	Open Select	
Librarians	Dove Medical Press	
Societies	F1000Research	
Opportunities	Help and information	
Reprints and e-prints	Help and contact	
Advertising solutions	Newsroom	
Accelerated publication	All journals	
Corporate access solutions	Books	

Keep up to date

Register to receive personalised research and resources by email





Copyright © 2025 Informa UK Limited Privacy policy Cookies Terms & conditions Accessibility

Taylor & Francis Group an informa business

Registered in England & Wales No. 01072954 5 Howick Place | London | SW1P 1WG